Taiwan FDA approves Moderna’s COVID-19 vaccine for SARS-COV-2 variant JN.1

Moderna announced that the Taiwan Food & Drug Administration has approved an updated formulation of the COVID-19 mRNA vaccine Spikevax, targeting the SARS-CoV-2 variant JN.1, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. In April 2024, the World Health Organization Technical Advisory Group on COVID-19 Vaccine Composition issued guidance recommending the use of a monovalent JN.1 lineage for COVID-19 vaccine antigen composition.